Report Detail

Pharma & Healthcare Global Bacillus Calmette Guerin Vaccine Market Insights, Forecast to 2028

  • RnM4459605
  • |
  • 30 June, 2022
  • |
  • Global
  • |
  • 118 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

Market Analysis and Insights: Global Bacillus Calmette Guerin Vaccine Market
Bacillus Calmette Guerin Vaccine provides immunity or protection against tuberculosis (TB). The vaccine may be given to persons at high risk of developing TB.

Due to the COVID-19 pandemic, the global Bacillus Calmette Guerin Vaccine market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, Immune Type accounting for % of the Bacillus Calmette Guerin Vaccine global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals segment is altered to an % CAGR throughout this forecast period.

China Bacillus Calmette Guerin Vaccine market size is valued at US$ million in 2021, while the US and Europe Bacillus Calmette Guerin Vaccine are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Bacillus Calmette Guerin Vaccine landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.

The global key manufacturers of Bacillus Calmette Guerin Vaccine include Merck, Sanofi Pasteur, Japan BCG Lab, China National Biotec, AJ Vaccines, Serum Institute of India, Intervax, GSBPL and Statens Serum Institute, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

Market Segments

The authors of this research report have explored the key segments: Type and Application. The report offers an in-depth breakdown of type and application segments and their sub-segments. The lucrativeness and growth potential have been looked into by the industry experts in this report. This section of the report also provides sales and revenue forecast data by type and application segments based on sales, price, and revenue for the period 2017-2028. The specialists, to broaden the understanding of the users, have done value chain and raw material analysis in this section.

Segment by Type

Immune Type

Therapy Type

Segment by Application

Hospitals

Clinics

Others

Consequence of Covid-19 Pandemic

The authors of this study have enlightened the readers on the rise and effect of the Covid-19 outbreak on the development. They have investigated the changes brought about in the demand/supply side, consumption, supply chain, and sales/manufacturing. The readers will get familiar with the measures that have helped the key players to bring the Bacillus Calmette Guerin Vaccine market back to the pre-covid levels.

Trends & Prospects

In this segment of the report, the specialists have delved into the key growth opportunities that are likely to emerge. This will aid the key players to simplify complex issues related to business and frame future strategies to compete in this competitive environment. This section will certainly assist the players to boldly position their business.

By Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Competitive Outlook

In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and share analysis of the prominent players are also provided in this section. They have also provided reliable sales and revenue data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:

Merck

Sanofi Pasteur

Japan BCG Lab

China National Biotec

AJ Vaccines

Serum Institute of India

Intervax

GSBPL

Statens Serum Institute

Biomed Lublin

ANLIS Malbran

Fundação Ataulpho de Paiva

BB-NCIPD

Taj Pharmaceuticals

Bio Farma

Microgen

Torlakinstitut

Institut Pasteur de Tunis

IVAC

Frequently Asked Questions

Which is the most lucrative product segment in the Bacillus Calmette Guerin Vaccine market?

Which are the prominent strategies of the Bacillus Calmette Guerin Vaccine market players?

Which factors are increasing the competition in the Bacillus Calmette Guerin Vaccine market?

Which are the recommendations provided by the Bacillus Calmette Guerin Vaccine industry experts?

Which region will witness rewarding growth during the forecast period?

What factors will curb the Bacillus Calmette Guerin Vaccine market growth?

Which product segment will register the fastest growth rate in the Bacillus Calmette Guerin Vaccine market?

Which emerging trends will impact the Bacillus Calmette Guerin Vaccine market growth?

Which are the high-impact rendering factors in the Bacillus Calmette Guerin Vaccine market?

Which companies will maintain their lead on the Bacillus Calmette Guerin Vaccine market?


1 Study Coverage

  • 1.1 Bacillus Calmette Guerin Vaccine Product Introduction
  • 1.2 Market by Type
  • 1.2.1 Global Bacillus Calmette Guerin Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
  • 1.2.2 Immune Type
  • 1.2.3 Therapy Type
  • 1.3 Market by Application
  • 1.3.1 Global Bacillus Calmette Guerin Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
  • 1.3.2 Hospitals
  • 1.3.3 Clinics
  • 1.3.4 Others
  • 1.4 Study Objectives
  • 1.5 Years Considered
  • 2 Executive Summary

    • 2.1 Global Bacillus Calmette Guerin Vaccine Sales Estimates and Forecasts 2017-2028
    • 2.2 Global Bacillus Calmette Guerin Vaccine Revenue Estimates and Forecasts 2017-2028
    • 2.3 Global Bacillus Calmette Guerin Vaccine Revenue by Region: 2017 VS 2021 VS 2028
    • 2.4 Global Bacillus Calmette Guerin Vaccine Sales by Region
    • 2.4.1 Global Bacillus Calmette Guerin Vaccine Sales by Region (2017-2022)
  • 2.4.2 Global Sales Bacillus Calmette Guerin Vaccine by Region (2023-2028)
  • 2.5 Global Bacillus Calmette Guerin Vaccine Revenue by Region
  • 2.5.1 Global Bacillus Calmette Guerin Vaccine Revenue by Region (2017-2022)
  • 2.5.2 Global Bacillus Calmette Guerin Vaccine Revenue by Region (2023-2028)
  • 2.6 North America
  • 2.7 Europe
  • 2.8 Asia-Pacific
  • 2.9 Latin America
  • 2.10 Middle East & Africa
  • 3 Competition by Manufacturers

    • 3.1 Global Bacillus Calmette Guerin Vaccine Sales by Manufacturers
    • 3.1.1 Global Top Bacillus Calmette Guerin Vaccine Manufacturers by Sales (2017-2022)
  • 3.1.2 Global Bacillus Calmette Guerin Vaccine Sales Market Share by Manufacturers (2017-2022)
  • 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Bacillus Calmette Guerin Vaccine in 2021
  • 3.2 Global Bacillus Calmette Guerin Vaccine Revenue by Manufacturers
  • 3.2.1 Global Bacillus Calmette Guerin Vaccine Revenue by Manufacturers (2017-2022)
  • 3.2.2 Global Bacillus Calmette Guerin Vaccine Revenue Market Share by Manufacturers (2017-2022)
  • 3.2.3 Global Top 10 and Top 5 Companies by Bacillus Calmette Guerin Vaccine Revenue in 2021
  • 3.3 Global Bacillus Calmette Guerin Vaccine Sales Price by Manufacturers (2017-2022)
  • 3.4 Analysis of Competitive Landscape
  • 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Bacillus Calmette Guerin Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
  • 3.4.3 Global Bacillus Calmette Guerin Vaccine Manufacturers Geographical Distribution
  • 3.5 Mergers & Acquisitions, Expansion Plans
  • 4 Market Size by Type

    • 4.1 Global Bacillus Calmette Guerin Vaccine Sales by Type
    • 4.1.1 Global Bacillus Calmette Guerin Vaccine Historical Sales by Type (2017-2022)
  • 4.1.2 Global Bacillus Calmette Guerin Vaccine Forecasted Sales by Type (2023-2028)
  • 4.1.3 Global Bacillus Calmette Guerin Vaccine Sales Market Share by Type (2017-2028)
  • 4.2 Global Bacillus Calmette Guerin Vaccine Revenue by Type
  • 4.2.1 Global Bacillus Calmette Guerin Vaccine Historical Revenue by Type (2017-2022)
  • 4.2.2 Global Bacillus Calmette Guerin Vaccine Forecasted Revenue by Type (2023-2028)
  • 4.2.3 Global Bacillus Calmette Guerin Vaccine Revenue Market Share by Type (2017-2028)
  • 4.3 Global Bacillus Calmette Guerin Vaccine Price by Type
  • 4.3.1 Global Bacillus Calmette Guerin Vaccine Price by Type (2017-2022)
  • 4.3.2 Global Bacillus Calmette Guerin Vaccine Price Forecast by Type (2023-2028)
  • 5 Market Size by Application

    • 5.1 Global Bacillus Calmette Guerin Vaccine Sales by Application
    • 5.1.1 Global Bacillus Calmette Guerin Vaccine Historical Sales by Application (2017-2022)
  • 5.1.2 Global Bacillus Calmette Guerin Vaccine Forecasted Sales by Application (2023-2028)
  • 5.1.3 Global Bacillus Calmette Guerin Vaccine Sales Market Share by Application (2017-2028)
  • 5.2 Global Bacillus Calmette Guerin Vaccine Revenue by Application
  • 5.2.1 Global Bacillus Calmette Guerin Vaccine Historical Revenue by Application (2017-2022)
  • 5.2.2 Global Bacillus Calmette Guerin Vaccine Forecasted Revenue by Application (2023-2028)
  • 5.2.3 Global Bacillus Calmette Guerin Vaccine Revenue Market Share by Application (2017-2028)
  • 5.3 Global Bacillus Calmette Guerin Vaccine Price by Application
  • 5.3.1 Global Bacillus Calmette Guerin Vaccine Price by Application (2017-2022)
  • 5.3.2 Global Bacillus Calmette Guerin Vaccine Price Forecast by Application (2023-2028)
  • 6 North America

    • 6.1 North America Bacillus Calmette Guerin Vaccine Market Size by Type
    • 6.1.1 North America Bacillus Calmette Guerin Vaccine Sales by Type (2017-2028)
  • 6.1.2 North America Bacillus Calmette Guerin Vaccine Revenue by Type (2017-2028)
  • 6.2 North America Bacillus Calmette Guerin Vaccine Market Size by Application
  • 6.2.1 North America Bacillus Calmette Guerin Vaccine Sales by Application (2017-2028)
  • 6.2.2 North America Bacillus Calmette Guerin Vaccine Revenue by Application (2017-2028)
  • 6.3 North America Bacillus Calmette Guerin Vaccine Market Size by Country
  • 6.3.1 North America Bacillus Calmette Guerin Vaccine Sales by Country (2017-2028)
  • 6.3.2 North America Bacillus Calmette Guerin Vaccine Revenue by Country (2017-2028)
  • 6.3.3 United States
  • 6.3.4 Canada
  • 7 Europe

    • 7.1 Europe Bacillus Calmette Guerin Vaccine Market Size by Type
    • 7.1.1 Europe Bacillus Calmette Guerin Vaccine Sales by Type (2017-2028)
  • 7.1.2 Europe Bacillus Calmette Guerin Vaccine Revenue by Type (2017-2028)
  • 7.2 Europe Bacillus Calmette Guerin Vaccine Market Size by Application
  • 7.2.1 Europe Bacillus Calmette Guerin Vaccine Sales by Application (2017-2028)
  • 7.2.2 Europe Bacillus Calmette Guerin Vaccine Revenue by Application (2017-2028)
  • 7.3 Europe Bacillus Calmette Guerin Vaccine Market Size by Country
  • 7.3.1 Europe Bacillus Calmette Guerin Vaccine Sales by Country (2017-2028)
  • 7.3.2 Europe Bacillus Calmette Guerin Vaccine Revenue by Country (2017-2028)
  • 7.3.3 Germany
  • 7.3.4 France
  • 7.3.5 U.K.
  • 7.3.6 Italy
  • 7.3.7 Russia
  • 8 Asia Pacific

    • 8.1 Asia Pacific Bacillus Calmette Guerin Vaccine Market Size by Type
    • 8.1.1 Asia Pacific Bacillus Calmette Guerin Vaccine Sales by Type (2017-2028)
  • 8.1.2 Asia Pacific Bacillus Calmette Guerin Vaccine Revenue by Type (2017-2028)
  • 8.2 Asia Pacific Bacillus Calmette Guerin Vaccine Market Size by Application
  • 8.2.1 Asia Pacific Bacillus Calmette Guerin Vaccine Sales by Application (2017-2028)
  • 8.2.2 Asia Pacific Bacillus Calmette Guerin Vaccine Revenue by Application (2017-2028)
  • 8.3 Asia Pacific Bacillus Calmette Guerin Vaccine Market Size by Region
  • 8.3.1 Asia Pacific Bacillus Calmette Guerin Vaccine Sales by Region (2017-2028)
  • 8.3.2 Asia Pacific Bacillus Calmette Guerin Vaccine Revenue by Region (2017-2028)
  • 8.3.3 China
  • 8.3.4 Japan
  • 8.3.5 South Korea
  • 8.3.6 India
  • 8.3.7 Australia
  • 8.3.8 China Taiwan
  • 8.3.9 Indonesia
  • 8.3.10 Thailand
  • 8.3.11 Malaysia
  • 9 Latin America

    • 9.1 Latin America Bacillus Calmette Guerin Vaccine Market Size by Type
    • 9.1.1 Latin America Bacillus Calmette Guerin Vaccine Sales by Type (2017-2028)
  • 9.1.2 Latin America Bacillus Calmette Guerin Vaccine Revenue by Type (2017-2028)
  • 9.2 Latin America Bacillus Calmette Guerin Vaccine Market Size by Application
  • 9.2.1 Latin America Bacillus Calmette Guerin Vaccine Sales by Application (2017-2028)
  • 9.2.2 Latin America Bacillus Calmette Guerin Vaccine Revenue by Application (2017-2028)
  • 9.3 Latin America Bacillus Calmette Guerin Vaccine Market Size by Country
  • 9.3.1 Latin America Bacillus Calmette Guerin Vaccine Sales by Country (2017-2028)
  • 9.3.2 Latin America Bacillus Calmette Guerin Vaccine Revenue by Country (2017-2028)
  • 9.3.3 Mexico
  • 9.3.4 Brazil
  • 9.3.5 Argentina
  • 10 Middle East and Africa

    • 10.1 Middle East and Africa Bacillus Calmette Guerin Vaccine Market Size by Type
    • 10.1.1 Middle East and Africa Bacillus Calmette Guerin Vaccine Sales by Type (2017-2028)
  • 10.1.2 Middle East and Africa Bacillus Calmette Guerin Vaccine Revenue by Type (2017-2028)
  • 10.2 Middle East and Africa Bacillus Calmette Guerin Vaccine Market Size by Application
  • 10.2.1 Middle East and Africa Bacillus Calmette Guerin Vaccine Sales by Application (2017-2028)
  • 10.2.2 Middle East and Africa Bacillus Calmette Guerin Vaccine Revenue by Application (2017-2028)
  • 10.3 Middle East and Africa Bacillus Calmette Guerin Vaccine Market Size by Country
  • 10.3.1 Middle East and Africa Bacillus Calmette Guerin Vaccine Sales by Country (2017-2028)
  • 10.3.2 Middle East and Africa Bacillus Calmette Guerin Vaccine Revenue by Country (2017-2028)
  • 10.3.3 Turkey
  • 10.3.4 Saudi Arabia
  • 11 Company Profiles

    • 11.1 Merck
    • 11.1.1 Merck Corporation Information
  • 11.1.2 Merck Overview
  • 11.1.3 Merck Bacillus Calmette Guerin Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.1.4 Merck Bacillus Calmette Guerin Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.1.5 Merck Recent Developments
  • 11.2 Sanofi Pasteur
  • 11.2.1 Sanofi Pasteur Corporation Information
  • 11.2.2 Sanofi Pasteur Overview
  • 11.2.3 Sanofi Pasteur Bacillus Calmette Guerin Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.2.4 Sanofi Pasteur Bacillus Calmette Guerin Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.2.5 Sanofi Pasteur Recent Developments
  • 11.3 Japan BCG Lab
  • 11.3.1 Japan BCG Lab Corporation Information
  • 11.3.2 Japan BCG Lab Overview
  • 11.3.3 Japan BCG Lab Bacillus Calmette Guerin Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.3.4 Japan BCG Lab Bacillus Calmette Guerin Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.3.5 Japan BCG Lab Recent Developments
  • 11.4 China National Biotec
  • 11.4.1 China National Biotec Corporation Information
  • 11.4.2 China National Biotec Overview
  • 11.4.3 China National Biotec Bacillus Calmette Guerin Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.4.4 China National Biotec Bacillus Calmette Guerin Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.4.5 China National Biotec Recent Developments
  • 11.5 AJ Vaccines
  • 11.5.1 AJ Vaccines Corporation Information
  • 11.5.2 AJ Vaccines Overview
  • 11.5.3 AJ Vaccines Bacillus Calmette Guerin Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.5.4 AJ Vaccines Bacillus Calmette Guerin Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.5.5 AJ Vaccines Recent Developments
  • 11.6 Serum Institute of India
  • 11.6.1 Serum Institute of India Corporation Information
  • 11.6.2 Serum Institute of India Overview
  • 11.6.3 Serum Institute of India Bacillus Calmette Guerin Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.6.4 Serum Institute of India Bacillus Calmette Guerin Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.6.5 Serum Institute of India Recent Developments
  • 11.7 Intervax
  • 11.7.1 Intervax Corporation Information
  • 11.7.2 Intervax Overview
  • 11.7.3 Intervax Bacillus Calmette Guerin Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.7.4 Intervax Bacillus Calmette Guerin Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.7.5 Intervax Recent Developments
  • 11.8 GSBPL
  • 11.8.1 GSBPL Corporation Information
  • 11.8.2 GSBPL Overview
  • 11.8.3 GSBPL Bacillus Calmette Guerin Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.8.4 GSBPL Bacillus Calmette Guerin Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.8.5 GSBPL Recent Developments
  • 11.9 Statens Serum Institute
  • 11.9.1 Statens Serum Institute Corporation Information
  • 11.9.2 Statens Serum Institute Overview
  • 11.9.3 Statens Serum Institute Bacillus Calmette Guerin Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.9.4 Statens Serum Institute Bacillus Calmette Guerin Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.9.5 Statens Serum Institute Recent Developments
  • 11.10 Biomed Lublin
  • 11.10.1 Biomed Lublin Corporation Information
  • 11.10.2 Biomed Lublin Overview
  • 11.10.3 Biomed Lublin Bacillus Calmette Guerin Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.10.4 Biomed Lublin Bacillus Calmette Guerin Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.10.5 Biomed Lublin Recent Developments
  • 11.11 ANLIS Malbran
  • 11.11.1 ANLIS Malbran Corporation Information
  • 11.11.2 ANLIS Malbran Overview
  • 11.11.3 ANLIS Malbran Bacillus Calmette Guerin Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.11.4 ANLIS Malbran Bacillus Calmette Guerin Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.11.5 ANLIS Malbran Recent Developments
  • 11.12 Fundação Ataulpho de Paiva
  • 11.12.1 Fundação Ataulpho de Paiva Corporation Information
  • 11.12.2 Fundação Ataulpho de Paiva Overview
  • 11.12.3 Fundação Ataulpho de Paiva Bacillus Calmette Guerin Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.12.4 Fundação Ataulpho de Paiva Bacillus Calmette Guerin Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.12.5 Fundação Ataulpho de Paiva Recent Developments
  • 11.13 BB-NCIPD
  • 11.13.1 BB-NCIPD Corporation Information
  • 11.13.2 BB-NCIPD Overview
  • 11.13.3 BB-NCIPD Bacillus Calmette Guerin Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.13.4 BB-NCIPD Bacillus Calmette Guerin Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.13.5 BB-NCIPD Recent Developments
  • 11.14 Taj Pharmaceuticals
  • 11.14.1 Taj Pharmaceuticals Corporation Information
  • 11.14.2 Taj Pharmaceuticals Overview
  • 11.14.3 Taj Pharmaceuticals Bacillus Calmette Guerin Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.14.4 Taj Pharmaceuticals Bacillus Calmette Guerin Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.14.5 Taj Pharmaceuticals Recent Developments
  • 11.15 Bio Farma
  • 11.15.1 Bio Farma Corporation Information
  • 11.15.2 Bio Farma Overview
  • 11.15.3 Bio Farma Bacillus Calmette Guerin Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.15.4 Bio Farma Bacillus Calmette Guerin Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.15.5 Bio Farma Recent Developments
  • 11.16 Microgen
  • 11.16.1 Microgen Corporation Information
  • 11.16.2 Microgen Overview
  • 11.16.3 Microgen Bacillus Calmette Guerin Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.16.4 Microgen Bacillus Calmette Guerin Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.16.5 Microgen Recent Developments
  • 11.17 Torlakinstitut
  • 11.17.1 Torlakinstitut Corporation Information
  • 11.17.2 Torlakinstitut Overview
  • 11.17.3 Torlakinstitut Bacillus Calmette Guerin Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.17.4 Torlakinstitut Bacillus Calmette Guerin Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.17.5 Torlakinstitut Recent Developments
  • 11.18 Institut Pasteur de Tunis
  • 11.18.1 Institut Pasteur de Tunis Corporation Information
  • 11.18.2 Institut Pasteur de Tunis Overview
  • 11.18.3 Institut Pasteur de Tunis Bacillus Calmette Guerin Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.18.4 Institut Pasteur de Tunis Bacillus Calmette Guerin Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.18.5 Institut Pasteur de Tunis Recent Developments
  • 11.19 IVAC
  • 11.19.1 IVAC Corporation Information
  • 11.19.2 IVAC Overview
  • 11.19.3 IVAC Bacillus Calmette Guerin Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.19.4 IVAC Bacillus Calmette Guerin Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.19.5 IVAC Recent Developments
  • 12 Industry Chain and Sales Channels Analysis

    • 12.1 Bacillus Calmette Guerin Vaccine Industry Chain Analysis
    • 12.2 Bacillus Calmette Guerin Vaccine Key Raw Materials
    • 12.2.1 Key Raw Materials
  • 12.2.2 Raw Materials Key Suppliers
  • 12.3 Bacillus Calmette Guerin Vaccine Production Mode & Process
  • 12.4 Bacillus Calmette Guerin Vaccine Sales and Marketing
  • 12.4.1 Bacillus Calmette Guerin Vaccine Sales Channels
  • 12.4.2 Bacillus Calmette Guerin Vaccine Distributors
  • 12.5 Bacillus Calmette Guerin Vaccine Customers
  • 13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis

    • 13.1 Bacillus Calmette Guerin Vaccine Industry Trends
    • 13.2 Bacillus Calmette Guerin Vaccine Market Drivers
    • 13.3 Bacillus Calmette Guerin Vaccine Market Challenges
    • 13.4 Bacillus Calmette Guerin Vaccine Market Restraints

    14 Key Findings in The Global Bacillus Calmette Guerin Vaccine Study

      15 Appendix

      • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
    • 15.1.2 Data Source
    • 15.2 Author Details
    • Summary:
      Get latest Market Research Reports on Bacillus Calmette Guerin Vaccine. Industry analysis & Market Report on Bacillus Calmette Guerin Vaccine is a syndicated market report, published as Global Bacillus Calmette Guerin Vaccine Market Insights, Forecast to 2028. It is complete Research Study and Industry Analysis of Bacillus Calmette Guerin Vaccine market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,850.00
      $7,700.00
      3,072.30
      6,144.60
      3,595.90
      7,191.80
      601,639.50
      1,203,279.00
      321,436.50
      642,873.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report